60 Degrees Pharmaceutical... (SXTP)
NASDAQ: SXTP
· Real-Time Price · USD
2.25
-0.23 (-9.27%)
At close: May 02, 2025, 3:59 PM
2.34
4.00%
After-hours: May 02, 2025, 05:01 PM EDT
Company Description
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases.
The company offers Arakoda for malaria preventative treatment.
It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue.
The company was founded in 2010 and is based in Washington, District of Columbia.
60 Degrees Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jul 12, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Geoffrey Stuart Dow Ph.D. |
Contact Details
Address: 1025 Connecticut Avenue NW Washington, DC United States | |
| Website | https://60degreespharma.com |
Stock Details
| Ticker Symbol | SXTP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001946563 |
| CUSIP Number | 83006G104 |
| ISIN Number | US83006G1040 |
| Employer ID | 45-2406880 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geoffrey Stuart Dow Ph.D. | Chairman, Chief Executive Officer & President |
| Tyrone Miller | Chief Financial Officer & Treasurer |
| Dr. Bryan Smith | Chief Medical Officer |
| Kristen Landon | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 09, 2025 | 8-K | Current Report |
| Mar 27, 2025 | S-1/A | [Amend] Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | S-1 | Filing |
| Feb 12, 2025 | D | Filing |
| Feb 11, 2025 | D | Filing |
| Feb 11, 2025 | SCHEDULE 13G | Filing |
| Feb 06, 2025 | 8-K | Current Report |
| Feb 06, 2025 | 424B5 | Filing |